Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

12.06.17	Sanofi Announces Results From Two Phase 3b/4 ODYSSEY-DM Trials In Diabetes (RTTNews)
11.06.17	Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia (PR Newswire)
11.06.17	Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia (PR Newswire)
10.06.17	New Analysis Shows Sanofi's Soliqua® 100/33 Lowered HbA1c by More Than 2 Percent in Patients with Screening Levels Greater than 9 Percent (PR Newswire)
10.06.17	In Senior Adults Treated with Basal Insulin, Switching to Sanofi's Toujeo® Halved Hypoglycemia Risk (PR Newswire)
04.06.17	Regeneron, Sanofi Present Positive Study Results For PD-1 Antibody REGN2810 (RTTNews)
04.06.17	Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
01.06.17	Drug Makers Stocks on Investors' Radar -- AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Sanofi (PR Newswire)
22.05.17	Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (PR Newswire)
22.05.17	Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients (PR Newswire)
22.05.17	Diageo Brands Awarded Top Honors For Superior Quality At The 17th Annual San Francisco World Spirits Competition (PR Newswire)
08.05.17	Global Net Lease Announces Operating Results for First Quarter 2017 (PR Newswire)
03.05.17	NRCC Sisters in the Brotherhood to Hold 4th Annual Open House (PR Newswire)
02.05.17	Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment (PR Newswire)
02.05.17	Survey Results Show Eighty Percent of Rheumatoid Arthritis Patients Report Life-Altering Pain Daily or Multiple Times a Week, Despite Treatment (PR Newswire)
30.04.17	Monday Is D-Day For AEZS, Watch Out For MRUS, FDA Nod For RDUS & Takeda (RTTNews)
28.04.17	Sanofi Delivers Robust Q1 2017 Financial Results (PR Newswire)
28.04.17	Sanofi Stock Up As Q1 Profit Surges On Merial Disposal; Backs FY17 View (RTTNews)
28.04.17	Sanofi Q1 Profit Soars On Merial Disposal, Higher Sales; Backs FY17 View (RTTNews)
28.04.17	Sanofi: FDA Sets New Action Date For Kevzara BLA As May 22, 2017 - Quick Facts (RTTNews)
28.04.17	Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA (PR Newswire)
26.04.17	AKBA Jumps On Otsuka Deal, MNOV Abuzz, CAPR Counting On HOPE... (RTTNews)
25.04.17	Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection (PR Newswire)
25.04.17	D-Day For CAPR Today, OMED Hands Out Pink Slips, JAZZ Hits Right Notes... (RTTNews)
24.04.17	Sanofi Sues Mylan Over EpiPen Marketing (RTTNews)
24.04.17	Sanofi:FDA Oks Thymoglobulin For Prevention Of Acute Kidney Transplant Rejection (RTTNews)
24.04.17	Sanofi Receives FDA Approval of Thymoglobulin® for the Prevention of Acute Kidney Transplant Rejection (PR Newswire)
24.04.17	Sanofi, Regeneron Say Kevzara Gets CHMP Positive Opinion For RA In Adults (RTTNews)
19.04.17	Research Reports Initiation on Drug Makers Stocks -- Impax Labs, Sanofi, Heron Therapeutics, and Alimera Sciences (PR Newswire)
18.04.17	5 Stocks to Watch as Canada Gets Hooked on Cannabis (PR Newswire)
12.04.17	AZEK® Decking Named #1 in Quality in 2017 BUILDER Brand Use Study (PR Newswire)
04.04.17	FDA Nod For TEVA, Cheers For PRTK, SRNE Hits Goal, SNY Launches Kids Toothpaste (RTTNews)
04.04.17	Sanofi-Pasteur Agrees To Pay $19.9 Mln Fine For Drug Overcharges (RTTNews)
03.04.17	Sanofi Launches First-Ever ACT® Kids Toothpaste in the U.S. (PR Newswire)
03.04.17	Sanofi Launches First-Ever ACT® Kids Toothpaste in the U.S. (PR Newswire)
02.04.17	Switching to Sanofi's Toujeo® Showed Significant Reductions in Blood Sugar and Significantly Lower Incidence of Hypoglycemia in a Real-World Observational Study (PR Newswire)
29.03.17	First Drug For 2 Forms Of MS Gets FDA Nod, RTTR Abuzz, VRTX Gains On Trial Data (RTTNews)
29.03.17	Regeneron Says FDA Okays New Eczema Drug Dupixent (RTTNews)
28.03.17	Regeneron and Sanofi to Host Investor Conference Call to Discuss DUPIXENT® (dupilumab) Approval (PR Newswire)
28.03.17	Sanofi and Regeneron Announce FDA Approval of Dupixent® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
28.03.17	Regeneron and Sanofi Announce FDA Approval of DUPIXENT® (dupilumab), the First Targeted Biologic Therapy for Adults with Moderate-to-Severe Atopic Dermatitis (PR Newswire)
27.03.17	VIVUS In Deal To Reacquire STENDRA Commercial Rights From Sanofi - Quick Facts (RTTNews)
21.03.17	Sanofi's Study Says Allergy Sufferer's Sleep To Be Disrupted 4 Times Than Normal (RTTNews)
21.03.17	Sanofi Announces Results of First-of-Its-Kind Social Experiment Revealing Real-Life Impact of Symptoms on Allergy Sufferers in the U.S. (PR Newswire)
14.03.17	Sanofi et Voluntis annoncent une alliance mondiale visant à fournir des solutions numériques de titrage de l'insuline aux personnes atteintes de diabète de type 2 (PR Newswire)
14.03.17	UK Patients Granted Early Access to Sanofi's Innovative Dermatology Treatment Dupilumab by MHRA (PR Newswire)
14.03.17	Sanofi und Voluntis verkünden globale Partnerschaft zur Vermarktung digitaler Insulintitrationslösungen für Patienten mit Typ-2-Diabetes (PR Newswire)
14.03.17	How These Drug Makers Stocks are Faring? -- Sanofi, Impax Laboratories, Heron Therapeutics, and GW Pharma (PR Newswire)
14.03.17	Sanofi and Voluntis Announce a Global Alliance to Deliver Digital Insulin Titration Solutions for People with Type 2 Diabetes (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

17.10.24		Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden
04.10.24		Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar
12.09.24		Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach
11.09.24		Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer
02.09.24		Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert
04.07.24		Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht
03.07.24		Sanofi-Aktie moderat im Plus: Dupixent von Sanofi erhält EU-Zulassung für COPD-Behandlung
26.06.24		Sanofi-Aktie im Minus: Verkauf von Consumer Health steht offenbar in den Startlöchern - möglicher IPO

17.10.24

Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden

04.10.24

Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar

12.09.24

Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach

11.09.24

Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer

02.09.24

Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert

04.07.24

Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht